{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:38:34Z","timestamp":1792571914048,"version":"4.5.0"},"reference-count":36,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Poor immune reconstitution after haploidentical stem cell transplantation results in a high mortality from viral infections and relapse. One approach to overcome this problem is to selectively deplete the graft of alloreactive cells using an immunotoxin directed against the activation marker CD25. However, the degree of depletion of alloreactive cells is variable following stimulation with recipient peripheral blood mononuclear cells (PBMCs), and this can result in graft versus host disease (GVHD). We have refined this approach using recipient Epstein-Barr virus (EBV)\u2013transformed lymphoblastoid cell lines (LCLs) as stimulators to activate donor alloreactive T cells. Our studies demonstrate that allodepletion with an anti-CD25 immunotoxin following stimulation with HLA-mismatched host LCLs more consistently depleted in vitro alloreactivity than stimulation with host PBMCs, as assessed in primary mixed lymphocyte reactions (MLRs). Allodepletion using this approach specifically abrogates cytotoxic T-cell responses against host LCLs. In interferon-\u03b3 (IFN-\u03b3) enzyme-linked immunospot (ELISPOT) assays, antiviral responses to adenovirus and cytomegalovirus (CMV) were preserved following allodepletion. Likewise, using HLA-A2\u2013pp65 tetramers, we have shown that the frequency of CMV-specific T cells is unaffected by allodepletion. Moreover, the donor anti-EBV response is partially retained by recognition of EBV antigens through the nonshared haplotype. Finally, we studied whether allodepletion affects the response to candidate tumor antigens in myeloid malignancies. Using HLA-A2\u2013PR1 tetramer analysis, we found that the frequency of T cells recognizing the PR1 epitope of proteinase 3 was not significantly different in allodepleted and unmanipulated PBMCs from patients with chronic myeloid leukemia (CML) undergoing transplantation. Based on these data, we have embarked on a phase 1 clinical trial of addback of allo-LCL\u2013depleted donor T cells in the haplo-identical setting.<\/jats:p>","DOI":"10.1182\/blood-2002-11-3516","type":"journal-article","created":{"date-parts":[[2003,5,27]],"date-time":"2003-05-27T00:16:07Z","timestamp":1053994567000},"page":"2292-2299","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":120,"title":["Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses"],"prefix":"10.1182","volume":"102","author":[{"given":"Persis J.","family":"Amrolia","sequence":"first","affiliation":[{"name":"From the Department of Bone Marrow Transplantation, Great Ormond St Childrens Hospital, London, United Kingdom; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and Department of Bone Marrow Transplantation, MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Muccioli-Casadei","sequence":"additional","affiliation":[{"name":"From the Department of Bone Marrow Transplantation, Great Ormond St Childrens Hospital, London, United Kingdom; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and Department of Bone Marrow Transplantation, MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Yvon","sequence":"additional","affiliation":[{"name":"From the Department of Bone Marrow Transplantation, Great Ormond St Childrens Hospital, London, United Kingdom; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and Department of Bone Marrow Transplantation, MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Huls","sequence":"additional","affiliation":[{"name":"From the Department of Bone Marrow Transplantation, Great Ormond St Childrens Hospital, London, United Kingdom; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and Department of Bone Marrow Transplantation, MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uluhan","family":"Sili","sequence":"additional","affiliation":[{"name":"From the Department of Bone Marrow Transplantation, Great Ormond St Childrens Hospital, London, United Kingdom; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and Department of Bone Marrow Transplantation, MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Wieder","sequence":"additional","affiliation":[{"name":"From the Department of Bone Marrow Transplantation, Great Ormond St Childrens Hospital, London, United Kingdom; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and Department of Bone Marrow Transplantation, MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bollard","sequence":"additional","affiliation":[{"name":"From the Department of Bone Marrow Transplantation, Great Ormond St Childrens Hospital, London, United Kingdom; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and Department of Bone Marrow Transplantation, MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslav","family":"Michalek","sequence":"additional","affiliation":[{"name":"From the Department of Bone Marrow Transplantation, Great Ormond St Childrens Hospital, London, United Kingdom; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and Department of Bone Marrow Transplantation, MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Ghetie","sequence":"additional","affiliation":[{"name":"From the Department of Bone Marrow Transplantation, Great Ormond St Childrens Hospital, London, United Kingdom; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and Department of Bone Marrow Transplantation, MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen E.","family":"Heslop","sequence":"additional","affiliation":[{"name":"From the Department of Bone Marrow Transplantation, Great Ormond St Childrens Hospital, London, United Kingdom; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and Department of Bone Marrow Transplantation, MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Molldrem","sequence":"additional","affiliation":[{"name":"From the Department of Bone Marrow Transplantation, Great Ormond St Childrens Hospital, London, United Kingdom; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and Department of Bone Marrow Transplantation, MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cliona M.","family":"Rooney","sequence":"additional","affiliation":[{"name":"From the Department of Bone Marrow Transplantation, Great Ormond St Childrens Hospital, London, United Kingdom; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and Department of Bone Marrow Transplantation, MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Schlinder","sequence":"additional","affiliation":[{"name":"From the Department of Bone Marrow Transplantation, Great Ormond St Childrens Hospital, London, United Kingdom; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and Department of Bone Marrow Transplantation, MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Vitetta","sequence":"additional","affiliation":[{"name":"From the Department of Bone Marrow Transplantation, Great Ormond St Childrens Hospital, London, United Kingdom; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and Department of Bone Marrow Transplantation, MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm K.","family":"Brenner","sequence":"additional","affiliation":[{"name":"From the Department of Bone Marrow Transplantation, Great Ormond St Childrens Hospital, London, United Kingdom; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; and Department of Bone Marrow Transplantation, MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021217285539400_REF1","doi-asserted-by":"crossref","unstructured":"Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998; 339: 1186-1193.","DOI":"10.1056\/NEJM199810223391702"},{"key":"2020021217285539400_REF2","doi-asserted-by":"crossref","unstructured":"Handgretinger R, Schumm M, Lang P, et al. Transplantation of megadoses of purified haploidentical stem cells. Ann N Y Acad Sci. 1999; 872: 351-361.","DOI":"10.1111\/j.1749-6632.1999.tb08479.x"},{"key":"2020021217285539400_REF3","unstructured":"Haddad E, Landais P, Friedrich W, et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood. 1998;91: 3646-3653."},{"key":"2020021217285539400_REF4","doi-asserted-by":"crossref","unstructured":"Eyrich M, Lang P, Lal S, et al. A prospective analysis of the pattern of immune reconstitution in a paediatric cohort following transplantation of positively selected human leucocyte antigen-disparate haematopoietic stem cells from parental donors. Br J Haematol. 2001;114: 422-432.","DOI":"10.1046\/j.1365-2141.2001.02934.x"},{"key":"2020021217285539400_REF5","doi-asserted-by":"crossref","unstructured":"Gribben JG, Guinan EC, Boussiotis VA, et al. Complete blockade of B7 family-mediated co-stimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Blood. 1996;87: 4887-4893.","DOI":"10.1182\/blood.V87.11.4887.bloodjournal87114887"},{"key":"2020021217285539400_REF6","doi-asserted-by":"crossref","unstructured":"Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 1999;340: 1704-1714.","DOI":"10.1056\/NEJM199906033402202"},{"key":"2020021217285539400_REF7","doi-asserted-by":"crossref","unstructured":"van Dijk AM, Kessler FL, Stadhouders-Keet SA, et al. Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft-versus-host disease. Br J Haematol. 1999;107: 169-175.","DOI":"10.1046\/j.1365-2141.1999.01675.x"},{"key":"2020021217285539400_REF8","unstructured":"Valteau-Couanet D, Cavazzana-Calvo M, Le Deist F, Fromont C, Fischer A. Functional study of residual T lymphocytes after specific elimination of alloreactive T cells by a specific anti-interleukin-2 receptor Bk chain immunotoxin. Transplantation. 1993;56: 1574-1576."},{"key":"2020021217285539400_REF9","doi-asserted-by":"crossref","unstructured":"Montagna D, Yvon E, Calcaterra V, et al. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood. 1999;93: 3550-3557.","DOI":"10.1182\/blood.V93.10.3550.410k24_3550_3557"},{"key":"2020021217285539400_REF10","doi-asserted-by":"crossref","unstructured":"Cavazzana-Calvo M, Andre-Schmutz I, Hacein-Bey S, et al. T-cell-depleted HLA non-identical bone marrow transplantation in the child: prevention of graft-versus-host reaction by administration of donor T lymphocytes alloreactive against the recipient [in French]. J Soc Biol. 2001;195: 65-68.","DOI":"10.1051\/jbio\/2001195010065"},{"key":"2020021217285539400_REF11","doi-asserted-by":"crossref","unstructured":"Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1\/2 study. Lancet. 2002; 360: 130-137.","DOI":"10.1016\/S0140-6736(02)09413-8"},{"key":"2020021217285539400_REF12","doi-asserted-by":"crossref","unstructured":"Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92: 1549-1555.","DOI":"10.1182\/blood.V92.5.1549"},{"key":"2020021217285539400_REF13","doi-asserted-by":"crossref","unstructured":"Ghetie V, Thorpe P, Ghetie MA, et al. The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond. J Immunol Methods. 1991;142: 223-230.","DOI":"10.1016\/0022-1759(91)90110-2"},{"key":"2020021217285539400_REF14","doi-asserted-by":"crossref","unstructured":"Smith CA, Ng CY, Heslop HE, et al. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother. 1995;4: 73-79.","DOI":"10.1089\/scd.1.1995.4.73"},{"key":"2020021217285539400_REF15","doi-asserted-by":"crossref","unstructured":"Rooney CM, Wimperis JZ, Brenner MK, et al. Natural killer cell activity following T-cell depleted allogeneic bone marrow transplantation. Br J Haematol. 1986;62: 413-420.","DOI":"10.1111\/j.1365-2141.1986.tb02952.x"},{"key":"2020021217285539400_REF16","doi-asserted-by":"crossref","unstructured":"Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2: 551-555.","DOI":"10.1038\/nm0596-551"},{"key":"2020021217285539400_REF17","doi-asserted-by":"crossref","unstructured":"Savoldo B, Cubbage ML, Durett AG, et al. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002; 168: 909-918.","DOI":"10.4049\/jimmunol.168.2.909"},{"key":"2020021217285539400_REF18","doi-asserted-by":"crossref","unstructured":"Murray RJ, Kurilla MG, Brooks JM, et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med. 1992;176: 157-168.","DOI":"10.1084\/jem.176.1.157"},{"key":"2020021217285539400_REF19","doi-asserted-by":"crossref","unstructured":"Shayakhmetov DM, Lieber A. Dependence of adenovirus infectivity on length of the fiber shaft domain. J Virol. 2000;74: 10274-10286.","DOI":"10.1128\/JVI.74.22.10274-10286.2000"},{"key":"2020021217285539400_REF20","doi-asserted-by":"crossref","unstructured":"Davis AR, Meyers K, Wilson JM. High throughput method for creating and screening recombinant adenoviruses. Gene Ther. 1998;5: 1148-1152.","DOI":"10.1038\/sj.gt.3300705"},{"key":"2020021217285539400_REF21","doi-asserted-by":"crossref","unstructured":"Molldrem J, Dermime S, Parker K, et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 1996;88: 2450-2457.","DOI":"10.1182\/blood.V88.7.2450.bloodjournal8872450"},{"key":"2020021217285539400_REF22","doi-asserted-by":"crossref","unstructured":"Molldrem JJ, Clave E, Jiang YZ, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 1997; 90: 2529-2534.","DOI":"10.1182\/blood.V90.7.2529"},{"key":"2020021217285539400_REF23","doi-asserted-by":"crossref","unstructured":"Cavazzana-Calvo M, Fromont C, Le Deist F, et al. Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin. Transplantation. 1990;50: 1-7.","DOI":"10.1097\/00007890-199007000-00001"},{"key":"2020021217285539400_REF24","doi-asserted-by":"crossref","unstructured":"Koh MB, Prentice HG, Corbo M, et al. Alloantigen-specific T-cell depletion in a major histocompatibility complex fully mismatched murine model provides effective graft-versus-host disease prophylaxis in the presence of lymphoid engraftment. Br J Haematol. 2002;118: 108-116.","DOI":"10.1046\/j.1365-2141.2002.03682.x"},{"key":"2020021217285539400_REF25","doi-asserted-by":"crossref","unstructured":"Koh MB, Prentice HG, Lowdell MW. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis. Bone Marrow Transplant. 1999;23: 1071-1079.","DOI":"10.1038\/sj.bmt.1701749"},{"key":"2020021217285539400_REF26","doi-asserted-by":"crossref","unstructured":"Moris A, Teichgraber V, Gauthier L, Buhring HJ, Rammensee HG. Cutting edge: characterization of allorestricted and peptide-selective alloreactive T cells using HLA-tetramer selection. J Immunol. 2001;166: 4818-4821.","DOI":"10.4049\/jimmunol.166.8.4818"},{"key":"2020021217285539400_REF27","doi-asserted-by":"crossref","unstructured":"Ashwell JD, Chen C, Schwartz RH. High frequency and nonrandom distribution of alloreactivity in T cell clones selected for recognition of foreign antigen in association with self class II molecules. J Immunol. 1986;136: 389-395.","DOI":"10.4049\/jimmunol.136.2.389"},{"key":"2020021217285539400_REF28","unstructured":"Lombardi G, Lechler R. The molecular basis of allorecognition of major histocompatibility complex molecules by T lymphocytes. Ann Ist Super Sanita. 1991;27: 7-14."},{"key":"2020021217285539400_REF29","doi-asserted-by":"crossref","unstructured":"Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12: 991-1045.","DOI":"10.1146\/annurev.iy.12.040194.005015"},{"key":"2020021217285539400_REF30","doi-asserted-by":"crossref","unstructured":"Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000;95: 2198-2203.","DOI":"10.1182\/blood.V95.7.2198"},{"key":"2020021217285539400_REF31","doi-asserted-by":"crossref","unstructured":"Scheibenbogen C, Letsch A, Thiel E, et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood. 2002;100: 2132-2137.","DOI":"10.1182\/blood-2002-01-0163"},{"key":"2020021217285539400_REF32","doi-asserted-by":"crossref","unstructured":"Mavroudis DA, Dermime S, Molldrem J, et al. Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions. Br J Haematol. 1998;101: 565-570.","DOI":"10.1046\/j.1365-2141.1998.00748.x"},{"key":"2020021217285539400_REF33","doi-asserted-by":"crossref","unstructured":"Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6: 1018-1023.","DOI":"10.1038\/79526"},{"key":"2020021217285539400_REF34","doi-asserted-by":"crossref","unstructured":"Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295: 2097-2100.","DOI":"10.1126\/science.1068440"},{"key":"2020021217285539400_REF35","doi-asserted-by":"crossref","unstructured":"Trinchieri G. Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis. Semin Immunol. 1995;7: 83-88.","DOI":"10.1006\/smim.1995.0012"},{"key":"2020021217285539400_REF36","doi-asserted-by":"crossref","unstructured":"Lowdell MW, Craston R, Ray N, et al. The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia. Bone Marrow Transplant. 1998;21: 679-686.","DOI":"10.1038\/sj.bmt.1701153"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/6\/2292\/1690887\/h81803002292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/6\/2292\/1690887\/h81803002292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T09:16:05Z","timestamp":1682500565000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/6\/2292\/17227\/Selective-depletion-of-donor-alloreactive-T-cells"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9,15]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,9,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-11-3516","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9,15]]}}}